NASDAQ$ESPR
Esperion Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Esperion's financial performance significantly improved, marked by substantial revenue growth and strategic financial maneuvers.
Esperion reported a strong second quarter in 2024, highlighted by a 186% increase in total revenue to $73.8 million compared to the same period last year. The company also monetized its European royalties for $304.7 million and used the proceeds to pay off its Oberland revenue interest facility, enhancing financial flexibility. U.S. net product revenue grew by 39%, driven by increased retail prescription growth.
- Total revenue increased by 186% year-over-year to $73.8 million.
- U.S. net product revenue grew by 39% year-over-year, reaching $28.3 million.
- European royalties were monetized for $304.7 million, facilitating the payoff of the Oberland revenue interest facility.
- Retail prescription equivalents increased by 14% from the first quarter, with an 11% increase in the final four weeks of the second quarter.
Headline financials
Revenue & EPS history
Esperion · Revenue · Quarterly
$73.8M
Revenue by segment
Esperion · $34M total across 2 segments · Q3 2023
- U.S. Net Product Revenue$20.3M+44.6%59.6%
- Collaboration Revenue$13.7M+173.5%40.4%
Forward guidance
Esperion reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-2.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
19 / 44 earnings
Positive
+23.0%
Q3 2018
Best reaction
-47.6%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -0.6% | -0.3% | |
| Q4 2025 | -11.5% | -19.7% | -28.3% | |
| Q3 2025 | -15.0% | +5.4% | +26.9% | |
| Q1 2025 | -7.7% | -23.8% | +10.5% | |
| Q4 2024 | +12.0% | +7.0% | -18.4% | |
| Q3 2024 | +3.2% | +10.0% | +57.5% | |
| Q2 2024 | -10.9% | -3.0% | -13.9% | |
| Q1 2024 | -3.8% | +3.3% | +16.5% | |
| Q4 2023 | -2.3% | -3.0% | +1.9% | |
| Q3 2023 | +3.7% | -5.2% | +64.6% | |
| Q2 2023 | +14.0% | +3.8% | +1.9% | |
| Q1 2023 | +8.1% | +14.1% | +0.0% | |
| Q4 2022 | -3.9% | +4.7% | -73.6% | |
| Q3 2022 | -1.1% | +5.3% | -14.6% | |
| Q2 2022 | +5.9% | +11.9% | +41.1% | |
| Q1 2022 | +11.3% | -3.8% | -1.9% | |
| Q4 2021 | +5.5% | +9.1% | +32.8% | |
| Q3 2021 | +5.3% | +2.3% | -11.3% | |
| Q2 2021 | -6.6% | -5.2% | -12.7% | |
| Q1 2021 | -25.1% | -16.5% | -20.7% | |
| Q4 2020 | -0.2% | -4.2% | -1.9% | |
| Q3 2020 | -19.3% | -15.7% | -0.8% | |
| Q2 2020 | -11.9% | -13.7% | -0.1% | |
| Q1 2020 | +8.8% | +19.1% | +11.9% | |
| Q4 2019 | -11.5% | -5.4% | -38.1% | |
| Q3 2019 | -8.0% | -5.2% | +22.4% | |
| Q2 2019 | -2.0% | -2.3% | -9.6% | |
| Q1 2019 | +5.0% | +0.3% | +2.5% | |
| Q4 2018 | +1.2% | +0.7% | -14.1% | |
| Q3 2018 | +23.0% | +29.4% | +17.0% | |
| Q2 2018 | +3.2% | +4.2% | +10.6% | |
| Q1 2018 | -47.6% | -41.8% | -46.1% | |
| Q4 2017 | +1.2% | +5.3% | -6.1% | |
| Q3 2017 | -1.9% | +0.0% | +12.7% | |
| Q2 2017 | +11.9% | +9.2% | +10.4% | |
| Q3 2016 | -2.5% | -3.9% | +8.8% | |
| Q2 2016 | -1.0% | -2.2% | -4.2% | |
| Q1 2016 | -7.8% | — | — | |
| Q4 2015 | -3.4% | — | — | |
| Q3 2015 | -3.3% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +2.6% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro